valu usd unless otherwis note
investor frustrat justifi chang need
lower price target
view stock sell-off sent clear signal beyond
manag challeng forecast busi delay respond
industri chang govern frustrat contribut overli
punit sell-off send share back level struggl
stock leav rate unchang peer discount
seem justifi pressur board chang increas
lower ebitda billion billion billion
ep put new
ev/ebitda lower end group roughli point discount
teva street confid outlook like come fragil
given top-lin uncertainti low-end revenu rang
seemingli unclear spend guidance/expect
inabl consist hit guidanc rang remain wide leav
expect low lower target would still
meaning justifi discount group includ teva
understand capitul shorter-term focus
sell-off today last year share sinc
earli send messag board stock weak
valuat discount recent investor survey
link ask biggest risk upsid
leadership/corpor govern led respons far one
recur question heard investor drive
chang rest board dutch-bas compani
mean oper stakehold investor-focus
compani abil enact stitch approach hostil
activist way even attempt creat value/deliv return
reason teva acquir hostil per share
arguabl put power respons
hand board expect investor focu pick
particularli given board month lengthi strateg
review end sight today sell-off much
result today
appear manag continu avoid take
question earn call pose separ
five heard investor today answer
page specif sudden start ad back stock option
expens strateg review like lead anyth
manag visibl around spend go
europ call earlier uniqu
million new revenu realiz drive
growth ramp weight year
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
view well-posit long-term pipelin
diversifi revenu base learn
immun gener industri pressur
manag late capitul react led
steadi downward earn revis think
bottom stronger remain core base combin
emerg complex gener pipelin posit
share upward move follow primari driver
outperform thesi stock
face mani sector headwind
pressur peer given diversif activ
reposit think see growth improv
come year
sever import pipelin catalyst
drive support improv sentiment
long-term growth outlook still appear stabl
increasingli diversifi global footprint import
product swing factor remain restasi addit
potenti competit epipen gener copaxon
see lower growth peer
risk view three risk view
delay around pipelin convers and/or lower
expect uptak new launch impair
us base busi view weaker
appreci risk step-down ebitda
contribut inopportun use cash boost
upcom potenti catalyst event focu
greater expect gener advair ramp gener
restasi approv late feb target action date
pass strateg review updat fall investor day
addit accret use capit debt pay-down
bloomberg capit market estim upside/downside/target
base case scenario see stock price impli
price-to-earnings ep
steadi new gener approv activ high-singl digit
us gener eros base busi
continu ramp recent new product launch
gener copaxon fulphila gener advair
addit accret though assum
addit debt pay-down buyback outer year
upsid scenario see valu impli price-to-earnings
ep
inflect higher gener approv activ continu
accret supplement organ growth
portfolio addit debt pay-down buyback
limit competit high-valu gener greater-
downsid scenario see valu impli p/
 ep
greater competit pressur across us gener
portfolio lead lower expect new launch uptak
slowdown ou fail off-set pressur us
failur maintain steadi pipelin convers off-set
lot unansw question come look five
start ad back stock option expens
ep could ep full year
guidanc rang may seem overli materi
new call earn call mid larg cap gener
compani add back stock option expens
strateg review like lead anyth
sinc initi announc excess long time
manag quarter similar last indic review would
conclud near-term clear sinc time trade
result today word board continu
surprisingli lengthi review street number continu erod lower
stock low seen sinc
manag visibl around spend
unclear us februari link step spend guidanc
ep revenu shortli thereaft march link call
weight spend ep expect point
need support new launch happen roughli
three week left quarter today report sg roughli flat
year-over-year million consensu ad ep upsid
question would chang last march
manag better visibl around spend
spend go given youv alreadi launch major new product
spend presum go support
go europ call earlier uniqu
major impact million fx million due
serial europ investor unawar ahead quarter
overli materi amount come back anoth
neg surpris think call advanc one
seemingli impact peer teva sandoz
million new revenu realiz drive growth
ramp weight year
assumpt million new launch revenu ramp toward
billion limit upsid annual billion
revenu number get us billion versu billion billion rang
assum million per quarter europ come back total million
fx impact soften line sight bottom end guidanc rang
competit eros remain unknown manag credibl around
guidanc achiev low
exhibit
 incom guid hsd growth north guid msd growth eurest guid msd growth rowoth gener total revenu guid billioncost gross profit guid guid total revenuessg guid total revenuesoper incom incom incom tax incom guid incom prefer dividend adjust net guid billionep adjust guid dilut share guid million guid billion growth ebitda analysi margin guid guid total guid total revenuesoper expens guid net incom pharmaceuticals/specialti
price target base equal price-to-earnings ev/ebitda use target multipl
near sector low reflect concern around corpor
govern impli return price target support outperform rate
risk rate price target
risk rate price target includ limit extend delay key
product gener restasi impair us base busi
inopportun use cash boost leverag perpetu debt overhang
lead global gener manufactur base pittsburgh pennsylvania employ
approxim peopl global compani found transform
last sever year notabl acquisit merck kgaa
compani benefit differ revenu sourc help grow
eu auster headwind us comp strength recent year
